{"id":"NCT00732641","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7)","officialTitle":"Phase III Randomized, Prospective Multi-center Trial of PEG-Interferon α-2b as a Maintenance Therapy, Compared to Observation, in Patients With Multiple Myeloma Who Responded to Induction Therapy (Protocol No P01972)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2000-12","primaryCompletion":"2010-11","completion":"2010-11","firstPosted":"2008-08-12","resultsPosted":"2011-12-02","lastUpdate":"2017-04-04"},"enrollment":244,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Myeloma"],"interventions":[{"type":"DRUG","name":"Peginterferon","otherNames":[]}],"arms":[{"label":"Peginterferon α-2b","type":"EXPERIMENTAL"},{"label":"No Treatment","type":"NO_INTERVENTION"}],"summary":"This study aims to assess the efficacy of peginterferon α-2b, compared to a control arm not receiving any maintenance treatment, in adult subjects with multiple myeloma who have responded to a prior induction therapy. Peginterferon α-2b will be given once weekly as an injection until disease progression or relapse, or for up to a maximum of 5 years (whichever occurs first).","primaryOutcome":{"measure":"Number of Days With Progression Free Survival (PFS)","timeFrame":"Baseline and up to 5 years (or to the date of the first documented tumor progression or relapse)","effectByArm":[{"arm":"Peginterferon α-2b","deltaMin":1166,"sd":null},{"arm":"No Treatment","deltaMin":519,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":8},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":27,"n":123},"commonTop":["PYREXIA","INFLUENZA LIKE ILLNESS","ANAEMIA","ASTHENIA","BONE PAIN"]}}